NEW YORK (GenomeWeb) – Biocept said today that it has signed a provider agreement with Alliance Global to market and distribute its Target Selector liquid biopsy tests in the United Arab Emirates, as well as select countries in the Middle East, North and Sub-Saharan Africa, and Southeast Asia region.

Under the agreement, Biocept will perform all diagnostic testing services in its San Diego CLIA-certified laboratory. Alliance Global will be responsible for sales, marketing, distribution, and reimbursement. Additional terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.